CAS: 186413-79-6; 3-Amino-2-Methoxy-6-Picoline

相似化合物

1314922-96-7 112163-03-8 1785075-04-8

上下游产品

CAS号186413-76-3 2-甲基-5-硝基-6-甲氧基... | CAS号68957-50-6 2-氨基-3-硝基-5-溴-6-甲基吡啶 | CAS号186413-75-2 2-氯-3-硝基-5-溴-6-甲基吡啶 | CAS号186413-74-1 5-溴-2-羟基-3-硝基-6-甲基吡啶

2-氟-6-甲基-3-硝基吡啶置于10 Wt% Pd(Oh)2 On Carbon,甲酸铵,Sodium Hydride体系中,用 四氢呋喃,甲醇,Mineral Oil 用作溶剂,化学反应 39.0H,反应生成6-甲基-2-甲氧基-3-氨基吡啶
参考文献: Combination Of An Azetidine Lpa1 Receptor Antagonist With Pirfenidone And/or Nintedanib For Use In The Treatment Of Fibrotic Diseases[fr] Combinaison D'Un Antagoniste Du Récepteur Lpa1 De L'Azétidine Avec De La Pirfénidone Et/ou Du Nintedanib Destinée à être Utilisée Dans Le Traitement De Maladies Fibrotiques
标题: Combination Of An Azetidine Lpa1 Receptor Antagonist With Pirfenidone And/or Nintedanib For Use In The Treatment Of Fibrotic Diseases[fr] Combinaison D'Un Antagoniste Du Récepteur Lpa1 De L'Azétidine Avec De La Pirfénidone Et/ou Du Nintedanib Destinée à être Utilisée Dans Le Traitement De Maladies Fibrotiques
摘要:本发明涉及公式(i)中的化合物,其中r1,R2,R3,X和y如描述中所述,并且它们作为lpa1受体拮抗剂的使用,与一个或多个作为抗纤维化剂的治疗活性成分结合使用;例如特别是匹非尼酮和/或尼替达尼,在预防和/或治疗纤维化疾病方面.该发明还涉及包含公式(i)中的化合物与一个或多个作为抗纤维化剂的治疗活性成分(如匹非尼酮或尼替达尼)结合的药物组合物.

专利信息

专利号:EP-3904354-A1
优先权日:2020-04-30
标 题:New imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
权利人:PERHA PHARMACEUTICALS
摘要:The present invention relates to a compound of formula (I)n nwherein R 1 represents a (C 1 -C 6 )alkyl group, a spiro(C 5 -C 11 )bicyclic ring, a fused phenyl group, a substituted phenyl group, a R'-L- group, wherein L is either a single bond or a (Ci-C3)alkanediyl group, and R' represents a (C 3 -C 8 )cycloalkyl group, a bridged (C6-C 10 )cycloalkyl group, a (C 3 -C 8 )heterocycloalkyl group, or a (C 3 -C 8 )heteroaryl group, or a R'-L- group wherein L is a (Ci-C3)alkanediyl group, and R' is a an optionally substituted phenyl group or any of its pharmaceutically acceptable salt. n The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates. n It also relates to said compound for use as a medicament, in particular in the treatment and/or prevention of cognitive deficits associated with Down syndrome; Alzheimer's disease; dementia; tauopathies; Parkinson's disease; CDKL5 Deficiency Disorder; Phelan-McDermid syndrome; autism; diabetes; regulation of folate and methionine metabolism; osteoarthritis; Duchenne muscular dystrophy; several cancers; neuroinflammation, anemia and infections and for regulating body temperature.